Fig. 3From: A double-blind, randomized, multicenter, Italian study of frovatriptan versus rizatriptan for the acute treatment of migraineCumulative hazard of recurrence over the 48 h during treatment with frovatriptan (continuous line) or rizatriptan (dashed line), in the 125 patients of intention-to-treat population. Recurrence was defined according to protocolBack to article page